AAPL281.85-1.93 (-0.68%) ▼|ABBV255.27+1.92 (+0.76%) ▲|ABT92.83-1.29 (-1.37%) ▼|ACN125.04-3.94 (-3.05%) ▼|ADBE205.97+3.24 (+1.60%) ▲|AMAT697.48+70.64 (+11.27%) ▲|AMD536.72+15.14 (+2.90%) ▲|AMGN359.93+1.60 (+0.45%) ▲|AMT167.94-7.66 (-4.36%) ▼|AMZN240.09+7.40 (+3.18%) ▲|AVGO373.33+8.31 (+2.28%) ▲|AXP341.46+1.10 (+0.32%) ▲|BA215.26-1.99 (-0.92%) ▼|BAC58.04+0.16 (+0.28%) ▲|BKNG183.39+1.93 (+1.06%) ▲|BLK952.72-11.99 (-1.24%) ▼|BMY58.45+0.93 (+1.62%) ▲|BNY144.11+0.55 (+0.38%) ▲|BRK-B495.95-2.71 (-0.54%) ▼|C142.79+1.03 (+0.73%) ▲|CAT1,033.24+35.77 (+3.59%) ▲|CL91.98-0.09 (-0.10%) ▼|CMCSA24.44+1.27 (+5.46%) ▲|COF202.35-1.65 (-0.81%) ▼|COP104.43-1.53 (-1.44%) ▼|COST944.98-7.56 (-0.79%) ▼|CRM158.45+0.08 (+0.05%) ▲|CSCO117.47+3.70 (+3.25%) ▲|CVS103.36-0.98 (-0.94%) ▼|CVX168.84-2.22 (-1.30%) ▼|DE624.07+10.83 (+1.77%) ▲|DHR193.19-3.00 (-1.53%) ▼|DIS98.65-0.14 (-0.14%) ▼|DUK128.03-0.37 (-0.29%) ▼|EMR142.90-0.59 (-0.41%) ▼|FDX324.51+5.98 (+1.88%) ▲|GD348.45+1.74 (+0.50%) ▲|GE373.26+4.26 (+1.15%) ▲|GEV1,099.27+54.10 (+5.18%) ▲|GILD126.10-1.78 (-1.39%) ▼|GM77.52-0.59 (-0.75%) ▼|GOOG350.91+16.22 (+4.84%) ▲|GOOGL353.32+15.93 (+4.72%) ▲|GS1,023.93+4.32 (+0.42%) ▲|HD349.92+1.06 (+0.30%) ▲|HON227.58-15.84 (-6.51%) ▼|IBM277.65+6.02 (+2.22%) ▲|INTC130.38+2.06 (+1.61%) ▲|INTU267.20-0.52 (-0.19%) ▼|ISRG405.76+1.49 (+0.37%) ▲|JNJ257.94+3.28 (+1.29%) ▲|JPM330.84+1.79 (+0.54%) ▲|KO82.58-0.05 (-0.06%) ▼|LIN510.87-8.75 (-1.68%) ▼|LLY1,228.14+20.02 (+1.66%) ▲|LMT503.10-4.30 (-0.85%) ▼|LOW220.15-2.34 (-1.05%) ▼|LRCX409.83+30.74 (+8.11%) ▲|MA510.87+11.85 (+2.37%) ▲|MCD267.18-2.58 (-0.96%) ▼|MDLZ60.11-0.69 (-1.13%) ▼|MDT80.74-0.25 (-0.30%) ▼|META564.45+14.20 (+2.58%) ▲|MMM162.43-1.59 (-0.97%) ▼|MO73.85+0.06 (+0.08%) ▲|MRK129.36+0.70 (+0.54%) ▲|MS212.57+0.54 (+0.25%) ▲|MSFT368.04-4.93 (-1.32%) ▼|MU1,128.19-4.14 (-0.37%) ▼|NEE88.53-0.03 (-0.03%) ▼|NFLX73.88+0.07 (+0.09%) ▲|NKE41.32+0.57 (+1.40%) ▲|NOW99.83+1.49 (+1.52%) ▲|NVDA194.62+2.09 (+1.09%) ▲|ORCL148.25-0.28 (-0.19%) ▼|PEP138.10-3.29 (-2.33%) ▼|PFE24.41+0.12 (+0.49%) ▲|PG147.91-1.11 (-0.74%) ▼|PLTR116.21+3.28 (+2.90%) ▲|PM182.48+1.71 (+0.95%) ▲|QCOM187.52-1.88 (-0.99%) ▼|RTX187.74-0.25 (-0.13%) ▼|SBUX104.11-0.49 (-0.47%) ▼|SCHW90.52-0.16 (-0.17%) ▼|SO96.72-0.44 (-0.45%) ▼|SPG227.69+0.80 (+0.35%) ▲|T21.79-0.93 (-4.09%) ▼|TMO505.11-7.92 (-1.54%) ▼|TMUS173.83-8.86 (-4.85%) ▼|TSLA411.51+31.80 (+8.37%) ▲|TXN284.54-0.89 (-0.31%) ▼|UBER75.20-1.00 (-1.31%) ▼|UNH418.44-9.45 (-2.21%) ▼|UNP272.41+4.06 (+1.51%) ▲|UPS107.98-0.16 (-0.15%) ▼|USB61.40+0.49 (+0.80%) ▲|V342.23+6.00 (+1.78%) ▲|VZ44.09-2.45 (-5.26%) ▼|WFC83.84-0.03 (-0.03%) ▼|WMT114.83-0.86 (-0.74%) ▼|XOM136.09-0.46 (-0.33%) ▼|AAPL281.85-1.93 (-0.68%) ▼|ABBV255.27+1.92 (+0.76%) ▲|ABT92.83-1.29 (-1.37%) ▼|ACN125.04-3.94 (-3.05%) ▼|ADBE205.97+3.24 (+1.60%) ▲|AMAT697.48+70.64 (+11.27%) ▲|AMD536.72+15.14 (+2.90%) ▲|AMGN359.93+1.60 (+0.45%) ▲|AMT167.94-7.66 (-4.36%) ▼|AMZN240.09+7.40 (+3.18%) ▲|AVGO373.33+8.31 (+2.28%) ▲|AXP341.46+1.10 (+0.32%) ▲|BA215.26-1.99 (-0.92%) ▼|BAC58.04+0.16 (+0.28%) ▲|BKNG183.39+1.93 (+1.06%) ▲|BLK952.72-11.99 (-1.24%) ▼|BMY58.45+0.93 (+1.62%) ▲|BNY144.11+0.55 (+0.38%) ▲|BRK-B495.95-2.71 (-0.54%) ▼|C142.79+1.03 (+0.73%) ▲|CAT1,033.24+35.77 (+3.59%) ▲|CL91.98-0.09 (-0.10%) ▼|CMCSA24.44+1.27 (+5.46%) ▲|COF202.35-1.65 (-0.81%) ▼|COP104.43-1.53 (-1.44%) ▼|COST944.98-7.56 (-0.79%) ▼|CRM158.45+0.08 (+0.05%) ▲|CSCO117.47+3.70 (+3.25%) ▲|CVS103.36-0.98 (-0.94%) ▼|CVX168.84-2.22 (-1.30%) ▼|DE624.07+10.83 (+1.77%) ▲|DHR193.19-3.00 (-1.53%) ▼|DIS98.65-0.14 (-0.14%) ▼|DUK128.03-0.37 (-0.29%) ▼|EMR142.90-0.59 (-0.41%) ▼|FDX324.51+5.98 (+1.88%) ▲|GD348.45+1.74 (+0.50%) ▲|GE373.26+4.26 (+1.15%) ▲|GEV1,099.27+54.10 (+5.18%) ▲|GILD126.10-1.78 (-1.39%) ▼|GM77.52-0.59 (-0.75%) ▼|GOOG350.91+16.22 (+4.84%) ▲|GOOGL353.32+15.93 (+4.72%) ▲|GS1,023.93+4.32 (+0.42%) ▲|HD349.92+1.06 (+0.30%) ▲|HON227.58-15.84 (-6.51%) ▼|IBM277.65+6.02 (+2.22%) ▲|INTC130.38+2.06 (+1.61%) ▲|INTU267.20-0.52 (-0.19%) ▼|ISRG405.76+1.49 (+0.37%) ▲|JNJ257.94+3.28 (+1.29%) ▲|JPM330.84+1.79 (+0.54%) ▲|KO82.58-0.05 (-0.06%) ▼|LIN510.87-8.75 (-1.68%) ▼|LLY1,228.14+20.02 (+1.66%) ▲|LMT503.10-4.30 (-0.85%) ▼|LOW220.15-2.34 (-1.05%) ▼|LRCX409.83+30.74 (+8.11%) ▲|MA510.87+11.85 (+2.37%) ▲|MCD267.18-2.58 (-0.96%) ▼|MDLZ60.11-0.69 (-1.13%) ▼|MDT80.74-0.25 (-0.30%) ▼|META564.45+14.20 (+2.58%) ▲|MMM162.43-1.59 (-0.97%) ▼|MO73.85+0.06 (+0.08%) ▲|MRK129.36+0.70 (+0.54%) ▲|MS212.57+0.54 (+0.25%) ▲|MSFT368.04-4.93 (-1.32%) ▼|MU1,128.19-4.14 (-0.37%) ▼|NEE88.53-0.03 (-0.03%) ▼|NFLX73.88+0.07 (+0.09%) ▲|NKE41.32+0.57 (+1.40%) ▲|NOW99.83+1.49 (+1.52%) ▲|NVDA194.62+2.09 (+1.09%) ▲|ORCL148.25-0.28 (-0.19%) ▼|PEP138.10-3.29 (-2.33%) ▼|PFE24.41+0.12 (+0.49%) ▲|PG147.91-1.11 (-0.74%) ▼|PLTR116.21+3.28 (+2.90%) ▲|PM182.48+1.71 (+0.95%) ▲|QCOM187.52-1.88 (-0.99%) ▼|RTX187.74-0.25 (-0.13%) ▼|SBUX104.11-0.49 (-0.47%) ▼|SCHW90.52-0.16 (-0.17%) ▼|SO96.72-0.44 (-0.45%) ▼|SPG227.69+0.80 (+0.35%) ▲|T21.79-0.93 (-4.09%) ▼|TMO505.11-7.92 (-1.54%) ▼|TMUS173.83-8.86 (-4.85%) ▼|TSLA411.51+31.80 (+8.37%) ▲|TXN284.54-0.89 (-0.31%) ▼|UBER75.20-1.00 (-1.31%) ▼|UNH418.44-9.45 (-2.21%) ▼|UNP272.41+4.06 (+1.51%) ▲|UPS107.98-0.16 (-0.15%) ▼|USB61.40+0.49 (+0.80%) ▲|V342.23+6.00 (+1.78%) ▲|VZ44.09-2.45 (-5.26%) ▼|WFC83.84-0.03 (-0.03%) ▼|WMT114.83-0.86 (-0.74%) ▼|XOM136.09-0.46 (-0.33%) ▼|
30.5 C
New York
Monday, June 29, 2026

Tag: study

newssourceFORcompanyinformationcontent1releasesmarket

Ascidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of Stargardt...

BOSTON, June 24, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the appointment of Murray...

Sterotherapeutics Announces First Patient Dosed in Phase 2 Clinical Trial Evaluating ST-002 for Cushing’s Syndrome

DOYLESTOWN, Pa., June 24, 2025 /PRNewswire/ -- Sterotherapeutics LLC, a clinical-stage biopharmaceutical company focused on rare endocrine diseases, today announced that the first patient...

Abcentra Announces Appointment of Dr. Peter Libby as a Board Member as it Enters Orticumab’s Phase 2b Trial (FORTIFY)

LOS ANGELES, June 24, 2025 /PRNewswire/ -- Abcentra LLC (Abcentra), a clinical stage biotechnology company specializing in coronary artery disease, today announced the appointment...

York revealed as UK’s friendliest city, as Aviva research finds the nation’s community spirit is strong – but millions are without access to pubs...

Survey of over 6,000 people finds the UK is more trusting, friendly and community-minded than some may thinkThree quarters of people trust their neighbours (73%)...

71% Have Faced No Way To Dispose of Period Pads in Public Bathrooms, Study Reveals

New research from FLUUS revealed consumers have: Hidden pads up their sleeves because of a lack of appropriate binsWorn traditional pads for too long to the point...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

WIKATI Expands Global Footprint in Study Abroad Sector

HYDERABAD, India, June 24, 2025 /PRNewswire/ -- WIKATI, a trusted name in global education, announces the strategic expansion of its study abroad services to...

EMR June 2025 highlights growing monetization appeal of 5G fixed wireless access

More than half of all service providers globally who offer fixed wireless access now do so with speed-based monetization benefits enhanced by 5G5G subscriptions...

Evaluating the Financial Risks of Importing Indian Mangoes to the U.S.

In the realm of global fruit trade, the importation of Indian mangoes into New Jersey presents a compelling case study of market dynamics, risk...

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to...

For media and investors only

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors...

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reckitt Benckiser Group plc (OTC:RBGLY), UroGen Pharma Ltd. (NASDAQ:URGN), Red Cat Holdings, Inc. (NASDAQ: RCAT) and Fortrea Holdings Inc. (NASDAQ:FTRE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vestis, PepGen, and Tempus and Encourages Investors to Contact...

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Vestis Corporation (NYSE:VSTS), PepGen, Inc. (NASDAQ: PEPG), and Tempus AI, Inc. (NASDAQ: TEM). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStudy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers